News
GSK, Sanofi launch late-stage COVID-19 vaccine study
GlaxoSmithKline (GSK) and Sanofi have begun enrolling participants into a Phase III clinical study of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
GlaxoSmithKline (GSK) and Sanofi have begun enrolling participants into a Phase III clinical study of their adjuvanted recombinant-protein COVID-19 vaccine candidate.